25 results found.

Hemophilia B Clinical Trial using rIX-FP

CSL Behring - Recruiting N/A to 70 years.
- A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B.
rIX-FP

Hemophilia A Clinical Trial using Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

Baxter Healthcare Corporation - Recruiting N/A or older.
- ADVATE Hemophilia A Outcome Database.
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

Hemophilia A Clinical Trial using PF-05280602

Pfizer - Recruiting 18 years to 64 years.
- An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics / Pharmacodynamics Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors.
PF-05280602

Hemophilia A Clinical Trial using BAY94-9027

Bayer - Recruiting N/A to 12 years.
- A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A.
BAY94-9027

Hemophilia A Clinical Trial using BAY94-9027

Bayer - Recruiting 12 years to 65 years.
- A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A.
BAY94-9027

Hemophilia A, Hemophilia B, or Von Willebrand's Disease Clinical Trial

Karolinska University Hospital - Recruiting 10 years or older.
- GLOBAL HEMOSTATIC METHODS IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE CORRELATION WITH PATIENTS' CLINICAL STATUS AND USEFULNESS FOR TREATMENT MONITORING.

Hemophilia A Clinical Trial using Biostate

CSL Behring - Recruiting N/A to 11 years.
- A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to Evaluate Plasma-Derived Antihaemophilic Factor/Von Willebrand Factor Concentrate (Biostater) for Immune Tolerance Induction in Male Paediatric Subjects With Haemophilia A (ó 2%) Who Have Developed High-titre Antibodies to Factor VIII (Factor VIII Inhibitors).
Biostate

Haemophilia A Clinical Trial using Recombinant Factor VIII (BAY81-8973)

Bayer - Recruiting N/A to 12 years.
- A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy of BAY81-8973 in Children With Severe Hemophilia A Under Prophylaxis Therapy.
Recombinant Factor VIII (BAY81-8973)

Hemophilia A Clinical Trial using Laboratory Tests

Pfizer - Recruiting N/A to 5 years.
- An Open-Label Study Of The Safety And Efficacy Of ReFacto AF In Previously Untreated Patients In Usual Care Settings.
Laboratory Tests

Hemophilia B Clinical Trial using BeneFIX

Pfizer - Recruiting N/A or older.
- Pharmacovigilance Evaluation Of BeneFIX.
BeneFIX

Hepatitis C Virus Clinical Trial using Pegylated-Interferon-lambda; Ribavirin; Daclatasvir

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Na‹ve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin.
Pegylated-Interferon-lambda; Ribavirin; Daclatasvir

Hemophilia A Clinical Trial using Moroctocog alfa (AF-CC)

Pfizer - Recruiting N/A to 6 years.
- An Open-Label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics (PK) Of B Domain Deleted Recombinant Factor VIII Albumin Free (Moroctocog Alfa [AF-CC]) In Children With Hemophilia A.
Moroctocog alfa (AF-CC)

Hemophilia A Clinical Trial using Moroctocog alfa ( AF-CC); Laboratory tests

Pfizer - Recruiting N/A to 11 years.
- A Non-Randomized, Open-Label Study To Evaluate The Pharmacokinetics, Safety, And Efficacy Of ReFacto AF In Previously Treated Pediatric Subjects Less Than Twelve Years Of Age With Severe Hemophilia A (FVIII:C <1%).
Moroctocog alfa ( AF-CC); Laboratory tests

Hemophilia Clinical Trial using Recombinant Factor VIII (Kogenate, BAY14-2222)

Bayer - Recruiting 18 years or older.
- Evaluation of Efficacy, Safety and Costs of Recombinant FVIII Products Applied to Severe Hemophilia A Patients: Observational Data Collection Study Evaluating On-demand Treatment and Secondary Prophylaxis.
Recombinant Factor VIII (Kogenate, BAY14-2222)

Hemophilia A, or Hemophilia B Clinical Trial using ALN-AT3SC; Sterile Normal Saline (0.9% NaCl)

Alnylam Pharmaceuticals - Recruiting 18 years to 65 years.
- A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia).
ALN-AT3SC; Sterile Normal Saline (0.9% NaCl)

Hemophilia A Clinical Trial using PEGylated Recombinant factor VIII (rFVIII)

Baxter Healthcare Corporation - Recruiting 12 years to 65 years.
- A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures.
PEGylated Recombinant factor VIII (rFVIII)

Hemophilia A Clinical Trial using Recombinant Factor VIII (rFVIII)

CSL Behring - Recruiting 12 years to 65 years.
- A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study.
Recombinant Factor VIII (rFVIII)

Hemophilia A Clinical Trial using ReFacto AF (Moroctocog alfa)

Pfizer - Recruiting N/A or older.
- Pharmacovigilance Evaluation Of Refacto AF In Germany And Austria.
ReFacto AF (Moroctocog alfa)

Hemophilia A Clinical Trial using GreenGeneT F

Green Cross Corporation - Recruiting N/A or older.
- An Open Label Safety and Efficacy Extension Study of GreenGeneT F in Previously Treated Patients Diagnosed With Severe Hemophilia A.
GreenGeneT F

Hemophilia A Clinical Trial using GreenGeneT F and an approved recombinant Factor VIII product; GreenGeneT F

Green Cross Corporation - Recruiting 12 years or older.
- Determination of Safety, Efficacy and Pharmacokinetics of GreenGeneT F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A.
GreenGeneT F and an approved recombinant Factor VIII product; GreenGeneT F

Hemophilia B Clinical Trial using AAV8-hFIX19

Spark Therapeutics, LLC - Recruiting 18 years or older.
- A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX.
AAV8-hFIX19

Hemophilia B Clinical Trial using rIX-FP

CSL Behring - Recruiting N/A to 11 years.
- A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B.
rIX-FP

Hepatitis C With Hemophilia Clinical Trial using Lead -In- PegInterferon + Ribavirin (4 weeks); PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon + Ribavirin (8 weeks); No Lead-in - No 4-week lead in therapy; PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon+ Ribavirin (12 weeks)

University of Cincinnati - Recruiting 18 years or older.
- Viral Kinetic Models of HCV Clearance in Hemophiliacs With Telaprevir.
Lead -In- PegInterferon + Ribavirin (4 weeks); PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon + Ribavirin (8 weeks); No Lead-in - No 4-week lead in therapy; PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon+ Ribavirin (12 weeks)